Clin2
NCT06272214Possibly a fitRecruiting

Adjuvant radiotherapy for esophageal cancer after immunotherapy

Adjuvant Radiotherapy

Part of Cancer, Digestive system clinical trials.

This trial tests if adding radiation therapy after surgery improves outcomes for people with esophageal squamous cell cancer who received immunotherapy and chemotherapy before surgery but did not achieve a complete response. It aims to see if this approach can lower the chance of the cancer coming back.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
146 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have squamous cell carcinoma of the esophagus that was surgically removed (R0 resection).
  • You received 2 cycles of immunotherapy plus chemotherapy before surgery.
  • After surgery, the cancer did not completely disappear (non-pCR).
  • You are in generally good health, with adequate organ function (kidney, liver, heart, blood counts).
  • You agree to use effective contraception if applicable.
  • You do not have active autoimmune disease, uncontrolled infections, or a history of chest radiation.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06509568Recruiting· Phase 2
Chemoradiation plus immunotherapy before surgery for esophageal cancer

This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.

Hangzhou, Zhejiang
NCT07385664Not yet recruiting· Phase 2
Chemoimmunotherapy before surgery for esophageal cancer

This trial tests whether giving chemotherapy combined with immunotherapy before surgery works better than the standard chemoradiation for esophageal cancer that can be removed. It may help reduce tumor size and improve outcomes.

Hangzhou, Zhejiang
NCT04973306Recruiting· Phase 2/Phase 3
Chemo-immunotherapy before surgery versus chemo-radiation

This trial compares adding immunotherapy to standard chemo-radiation before surgery for locally advanced, operable esophageal squamous cell cancer. It aims to improve how well the tumor responds and whether patients do better after surgery.

Shanghai
NCT05760391Recruiting
Check anti-PD-1 therapy plus radiation for advanced esophageal cancer

This trial studies whether adding an anti-PD-1 immunotherapy (with chemotherapy) together with radiation can help people with advanced esophageal squamous cell cancer. It’s for cases where surgery or standard definitive chemoradiation can’t be done, or the cancer has spread to distant sites.

Shanghai
NCT06861894Not yet recruiting· Phase 2
Active monitoring after chemo-radiation plus immunotherapy for esophageal cancer

This trial tests a new approach for people with a certain type of esophageal cancer. Instead of surgery right away, you would receive chemotherapy, radiation, and an immunotherapy drug called adebrelimab. After that, doctors will closely watch your cancer to see if it's gone. The goal is to avoid surgery if the treatment works well.

Shanghai
NCT06602843Recruiting
Chemoimmunotherapy before and after surgery for esophageal cancer

This trial tests a treatment plan that combines chemotherapy and immunotherapy before surgery, followed by radiation and immunotherapy after surgery for people with esophageal squamous cell cancer. It aims to see if this approach helps prevent the cancer from coming back.

Hefei

Hear when a new Adjuvant Radiotherapy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.